Terragen Holdings posted a slight increase in net loss to AUD 3.75 million for FY2026, while advancing key commercial trials and securing a $7 million equity raise to fuel growth.
- FY2026 net loss of AUD 3.75 million
- Revenue down 11.3% to AUD 1.43 million
- Completed $7 million equity raising
- Major supply deal with Ravensworth Feedlot
- Progress in North American regulatory approvals
Financial Results Reflect Transition Phase
Terragen Holdings Limited (ASX:TGH) closed FY2026 with a net loss after tax of AUD 3.75 million, marginally wider than the previous year’s AUD 3.72 million. Revenue dipped 11.3% to AUD 1.43 million, impacted by drought conditions and slower-than-expected adoption of its new dry-format probiotic products. The company’s transition from product launch to commercial validation is evident in these numbers, as it supports customers shifting from its liquid probiotic Mylo® to the Terragen Probiotic for Ruminants™ range.
Operating expenses fell 6.9% year-on-year to AUD 5.98 million, notably with sales and marketing costs easing after the heavy launch spending in FY2025. However, research and development expenses increased to AUD 1.22 million as Terragen advanced its canine probiotic development and other strategic projects.
Capital Raise Strengthens Growth Potential
In February 2026, Terragen secured AUD 7 million via a share placement at AUD 0.022 per share, boosting issued capital to nearly AUD 57.9 million. This capital injection underpins the company’s ambitions to scale commercial adoption, enhance manufacturing capabilities, and pursue international market entry. Net assets rose to AUD 9.5 million, reflecting the capital raise offset by the year’s operating loss.
Commercial Milestones and Market Expansion
Terragen marked several operational highlights during FY2026. A landmark supply agreement with Ravensworth Feedlot in May 2026 represents the first large-scale commercial adoption of its probiotic and plant bio-stimulant products at scale. This deal complements the ongoing Mort & Co Grassdale feedlot trial involving over 10,000 cattle, designed to validate probiotic performance under commercial feedlot conditions.
Internationally, Terragen progressed regulatory approvals and trials in Canada, with Phase 1 of the Agriculture and Agri-Food Canada feedlot study completed and Phase 2 underway. The company is also advancing market access and manufacturing pathways in the United States and Brazil, signaling a clear focus on North American expansion.
The plant products portfolio showed promising results, highlighted by a 12% yield improvement in an independent maize silage trial for Great Land Plus®. The launch of Naturalift® extended Terragen’s microbial technology into the Australian home garden market, broadening its addressable market beyond commercial agriculture. Development of a companion animal probiotic also advanced towards commercialisation.
Governance and Strategic Focus
FY2026 saw key leadership changes, including the appointment of Dr Michele Allan AO as Non-Executive Chair and Daniel Pearce as Chief Financial Officer and Joint Company Secretary. The board and management emphasise disciplined investment, cost management, and strategic partnerships to accelerate technology adoption and revenue growth.
Terragen’s risk management framework addresses intellectual property protection, operational continuity, regulatory approvals, and market competition. The company continues to invest in research and development while managing financial risks and liquidity prudently.
What Lies Ahead for Terragen
Looking into FY2027, Terragen aims to convert scientific validation and commercial trials into sustainable revenue growth. Priorities include driving probiotic adoption through existing supply agreements and trials, advancing international expansion via regulatory approvals and partnerships, and broadening revenue streams by scaling plant and companion animal products. The company’s strengthened balance sheet and validated technology position it to pursue scalable commercial outcomes in Australia and abroad.
While the $7 million capital raise provides a runway for growth, the pace of large-scale feedlot adoption and the success of international regulatory pathways remain critical variables. Investors will be watching how Terragen navigates these operational challenges amid a competitive and evolving agricultural biotech landscape.
Terragen’s progress in commercial trials and international expansion, alongside continued R&D investment, sets the stage for potential inflection points in the coming year. Yet, the inherent uncertainties of market adoption cycles and regulatory environments mean the path to profitability remains cautious.
Major supply agreement and 12% maize yield boost further illustrate the company’s operational momentum, while the $7 million raise echoes the capital support detailed in cuts losses raises $7M.
Bottom Line?
Terragen’s FY2026 results underscore a company in transition, bolstered by fresh capital and commercial deals but still navigating the lengthy path from scientific validation to market scale.
Questions in the middle?
- How quickly can Terragen accelerate adoption in large-scale feedlots amid slower-than-expected uptake?
- What regulatory hurdles and timelines will define Terragen’s North American expansion?
- Can diversification into companion animal and consumer garden markets materially offset agricultural seasonality?